技术文章
人弥漫性大B细胞淋巴瘤细胞DoHH2
点击次数:69 发布时间:2022/8/3 16:33:58
商家名片
肖**
联系我时,请说明是阿仪网看到的,谢谢!
- 电话: 18******396
- 手机: 18******396
- 微信:
- 交换名片后展示联系方式 → →
细胞名称:人弥漫性大B细胞淋巴瘤细胞DoHH2
产品规格:T25培养瓶x1;1.5ml冻存管x2
细胞数量:1x10^6:1x10^6
保存温度:37℃;-198℃
运输方式:常温保温运输;干冰运输
安全等:1
用途限制
仅供科研2类培养体系
培养体系DMEM高糖培养基+10%FBS+1%三抗
培养温度37℃
二氧化碳浓度5%
简介
人弥漫性大B细胞淋巴瘤细胞DoHH2取自60岁男性,该细胞源于DSMZ
注释
Partof:CancerCellLineEncyclopedia(CCLE)project.
Partof:COSMICcelllinesproject.
Partof:LL-100bloodcancercelllinepanel.
Partof:MDAndersonCellLinesProject.
Partof:TCGA-110-CLcelllinepanel.
Doublingtime:48hours,inRPMI1640+5%FBS(PubMed=1849602);~40hours(DSMZ).
Microsatelliteinstability:Stable(MSS)(Sanger).
Transformant:NCBI_TaxID;10376;Epstein-Barrvirus(EBV).
Omics:Array-basedCGH.
Omics:Deepexomeanalysis.
Omics:DeepRNAseqanalysis.
Omics:DNAmethylationanalysis.
Omics:Genomesequenced.
Omics:H3K9acChIP-seqepigenomeanalysis.
Omics:Proteinexpressionbyreverse-phaseproteinarrays.
Omics:SNParrayanalysis.
Omics:Transcriptomeanalysis.
Omics:ViromeanalysisusingRNAseq.
Miscellaneous:OriginallyassignedtobefromaB-cellnon-Hodgkinlymphoma,immunoblastic-type.
Derivedfromsamplingsite:Pleuraleffusion.
基因突变
HLA信息
ClassI
HLA-AA*01:01,01:01
HLA-BB*08:01,44:02
HLA-CC*07:04,07:04
ClassII
HLA-DQDQA1*01:02,01:02
DQB1*05:01,06:02
HLA-DRDRB1*15:01,01:01
STR信息
AmelogeninX,Y
CSF1PO11,12
D3S135815,17
D5S81811,12
D7S82011
D8S117913,16
D13S31712,13
D16S53911,14
D18S5111,14
D21S1130
FGA21,27
PentaD9,12
PentaE12,16
TH019
TPOX8,11
vWA14,19
参考文献
PubMed=30285677;DOI=10.1186/s12885-018-4840-5
TanK.-T.,DingL.-W.,SunQ.-Y.,LaoZ.-T.,ChienW.,RenX.,XiaoJ.-F.,LohX.-Y.,XuL.,LillM.,MayakondaA.,LinD.-C.,YangH.,KoefflerH.P.
ProfilingtheB/Tcellreceptorrepertoireoflymphocytederivedcelllines.
BMCCancer18:940-940(2018)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
DutilJ.,ChenZ.,MonteiroA.N.,TeerJ.K.,EschrichS.A.
Aninteractiveresourcerobegeneticdiversityandestimatedancestryincancercelllines.
CancerRes.79:1263-1273(2019)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
GhandiM.,HuangF.W.,Jane-ValbuenaJ.,KryukovG.V.,LoC.C.,McDonaldE.R.III,BarretinaJ.,GelfandE.T.,BielskiC.M.,LiH.,HuK.,Andreev-DrakhlinA.Y.,KimJ.,HessJ.M.,HaasB.J.,AguetF.,WeirB.A.,RothbergM.V.,PaolellaB.R.,LawrenceM.S.,AkbaniR.,LuY.,TivH.L.,GokhaleP.C.,deWeckA.,MansourA.A.,OhC.,ShihJ.,HadiK.,RosenY.,BistlineJ.,VenkatesanK.,ReddyA.,SonkinD.,LiuM.,LeharJ.,KornJ.M.,PorterD.A.,JonesM.D.,GoljiJ.,CaponigroG.,TaylorJ.E.,DunningC.M.,CreechA.L.,WarrenA.C.,McFarlandJ.M.,ZamanighomiM.,KauffmannA.,StranskyN.,ImielinskiM.,MaruvkaY.E.,CherniackA.D.,TsherniakA.,VazquezF.,JaffeJ.D.,LaneA.A.,WeinstockD.M.,JohannessenC.M.,MorrisseyM.P.,StegmeierF.,SchlegelR.,HahnW.C.,GetzG.,MillsG.B.,BoehmJ.S.,GolubT.R.,GarrawayL.A.,SellersW.R.
Next-generationcharacterizationoftheCancerCellLineEncyclopedia.
Nature569:503-508(2019)
PubMed=31160637;DOI=10.1038/s41598-019-44491-x
QuentmeierH.,PommerenkeC.,DirksW.G.,EberthS.,KoeppelM.,MacLeodR.A.F.,NagelS.,SteubeK.,UphoffC.C.,DrexlerH.G.
TheLL-100panel:100celllinesforbloodcancerstudies.
Sci.Rep.9:8218-8218(2019)
PubMed=31395879;DOI=10.1038/s41467-019-11415-2
YuK.,ChenB.,AranD.,CharalelJ.,YauC.,WolfD.M.,van'tVeerL.J.,ButteA.J.,GoldsteinT.,SirotaM.
Comprehensivetranscriptomicanalysisofcelllinesasmodelsofprimarytumorsacross22tumortypes.
Nat.Commun.10:3574-3574(2019)
原创作者:智立中特(武汉)生物科技有限公司


